Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Validation of the Brazilian Version of Functional Assessment of Cancer Therapy-Prostate—FACT-P (Version 4) in Prostate Cancer Patients

Validation of the Brazilian Version of Functional Assessment of Cancer Therapy-Prostate—FACT-P... The purpose of this study is to validate the Brazilian version of Functional Assessment of Cancer Therapy-Prostate FACT-P (version 4) in nonmetastatic prostate cancer (PC) patients. Patients with histopathological diagnosis of PC were submitted to health-related quality of life (HRQOL) questionnaires – SF-36 (Medical Outcomes Study 36 – Item Short-Form Health Survey) and FACT-P (version 4). After 7 to 15 days, FACT-P (version 4) was reapplied in the sample’s percentage that participated the first evaluation. Cronbach alpha coefficient was used to determine internal consistency and intraclass correlation coefficient (ICC) certified stability. Correlations between FACT-P (version 4) and SF-36 tested convergent validity. Regarding known groups validity, the hypothesis tested was that FACT-P (version 4) is capable of discriminating HRQOL in patients with different PC risk classifications. A total of 112 patients with nonmetastatic PC were evaluated. Cronbach alpha coefficients (0.64–0.88) and ICC (0.75–0.93) obtained satisfactory results of reliability. Verified correlations (r 0.3–0.72) between FACT-P (version 4) and SF-36 suggest convergent validity. In the studied sample, FACT-P (version 4) was unable to discriminate HRQOL in nonmetastatic patients. The Brazilian version of FACT-P questionnaire (version 4) showed evidences of reliability and validity on evaluating HRQOL in Brazilian men with nonmetastatic PC. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Cancer Education Springer Journals

Validation of the Brazilian Version of Functional Assessment of Cancer Therapy-Prostate—FACT-P (Version 4) in Prostate Cancer Patients

Download PDF
8 pages

Loading next page...
 
/lp/springer-journals/validation-of-the-brazilian-version-of-functional-assessment-of-cancer-n3SMuSzajO
Publisher
Springer Journals
Copyright
Copyright © American Association for Cancer Education 2021
ISSN
0885-8195
eISSN
1543-0154
DOI
10.1007/s13187-021-02024-z
Publisher site
See Article on Publisher Site

Abstract

The purpose of this study is to validate the Brazilian version of Functional Assessment of Cancer Therapy-Prostate FACT-P (version 4) in nonmetastatic prostate cancer (PC) patients. Patients with histopathological diagnosis of PC were submitted to health-related quality of life (HRQOL) questionnaires – SF-36 (Medical Outcomes Study 36 – Item Short-Form Health Survey) and FACT-P (version 4). After 7 to 15 days, FACT-P (version 4) was reapplied in the sample’s percentage that participated the first evaluation. Cronbach alpha coefficient was used to determine internal consistency and intraclass correlation coefficient (ICC) certified stability. Correlations between FACT-P (version 4) and SF-36 tested convergent validity. Regarding known groups validity, the hypothesis tested was that FACT-P (version 4) is capable of discriminating HRQOL in patients with different PC risk classifications. A total of 112 patients with nonmetastatic PC were evaluated. Cronbach alpha coefficients (0.64–0.88) and ICC (0.75–0.93) obtained satisfactory results of reliability. Verified correlations (r 0.3–0.72) between FACT-P (version 4) and SF-36 suggest convergent validity. In the studied sample, FACT-P (version 4) was unable to discriminate HRQOL in nonmetastatic patients. The Brazilian version of FACT-P questionnaire (version 4) showed evidences of reliability and validity on evaluating HRQOL in Brazilian men with nonmetastatic PC.

Journal

Journal of Cancer Education – Springer Journals

Published: Dec 1, 2022

Keywords: Prostate cancer; FACT-P (version 4); Quality of life; Questionnaires; Validation

References

  • EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
    Mottet, N; Bellmunt, J; Bolla, M
  • Management of complications of prostate cancer treatment
    Michaelson, MD; Cotter, SE; Gargollo, PC; Zietman, AL; Dahl, DM; Smit, MR
  • When no treatment is the best treatment: active surveillance strategies for low risk prostate cancers
    Stavrinides, V; Parker, CC; Moore, CM
  • Long-term follow-up of a large active surveillance cohort of patients with prostate cancer
    Klotz, L; Vesprini, D; Sethukavalan, P; Jethava, V; Zhang, L; Jain, S
  • Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer
    Donovan, JL; Hamdy, FC; Lane, JA; Mason, M; Metcalfe, C; Walsh, E
  • Quality of life outcomes after primary treatment for clinically localised prostate cancer: a systematic review
    Lardas, M; Liew, M; van den Bergh, RC
  • Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study
    Drummond, FJ; Kinnear, H; O´Leary, E; Donnelly; Gavin, A; Sharp, L
  • Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments
    Schmidt, S; Garin, O; Pardo, Y; Valderas, JM; Alonso, J; Rebollo, P
  • Measuring health-related quality of life in men with prostate cancer: a systematic review of the most used questionnaires and their validity
    Hamoen, EHJ; Rooij, M; Witjes, JA; Barentsz, JO; Rovers, MM
  • Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
    Chi, KN; Protheroe, A; Rodríguez-Antolín, A; Facchini, G; Suttman, H; Matsubara, N
  • Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system
    Bonomi, AE; Celia, DF; Hahn, EA; Bjordai, K; Sperner-Unterweger, B; Gangeri, L
  • The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation
    Webster, K; Cella, D; Yost, K
  • The Functional Assessment of Cancer Therapy scale: development and validation of the general measure
    Cella, DF; Tulsky, DS; Gray, G
  • Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy - prostate instrument
    Esper, PEG; Mo, FEI; Chodak, G; Sinner, M; Cella, D; Pienta, KJ
  • Quality of life in second-line treatment of metastatic castration-resistant prostate cancer using cabazitaxel or other therapies after previous docetaxel chemotherapy: Swiss Observational Treatment Registry
    Stenner, F; Rothschild, SI; Betticher, D
  • A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy
    Fizazi, K; Ulys, A; Sengeløv, L
  • Detailed analysis of patient-reported lower urinary tract symptoms and effect on quality of life after robotic radical prostatectomy
    Aning, JJ; MacKenzie, KR; Fabricius, M
  • Quality criteria were proposed for measurements properties of health status questionnaires
    Terwee, CB; Bot, SDM; Boer, MR; Windt, AWM; Knol, DL; Dekker, J
  • A psychometric toolbox for testing validity and reliability
    DeVon, HA; Block, ME; Moyle-Wright, P; Ernst, DM; Hayden, SJ
  • Tradução para a língua portuguesa e validação do questionário genérico de avaliação de qualidade de vida SF-36 (Brasil SF-36)
    Ciconelli, RM; Ferraz, MB; Santos, W
  • Quality-of-life assessment tools for men with prostate cancer
    Bergman, J; Laviana, A
  • The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system
    Epstein, JI; Egevad, L; Amin, MB; Delahunt, B; Srigley, JR; Humphrey, PA
  • Sobre confiabilidade e validade
    Martins, GA
  • Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
    Chi, KN; Protheroe, A; Rodríguez-Antolín, A
  • Quality of life in prostate cancer patients and controls: psychometric validation of the FACTP-4 in Spanish, and relation to urinary symptoms
    Batista-Miranda, JE; Sevilla-Cecilia, C; Torrubia, R
  • “The worst thing was…”: prostate cancer patients’ evaluations of their diagnosis and treatment experiences
    Sharpley, CF; Bitsika, V; Christie, DRH
  • Sexual functioning in patients with localized prostate cancer awaiting treatment
    Incrocci, L; Madalinska, JB; Essink-Bot, M-L; Van Putten, WLJ; Koper, PCM; Schroeder, FH
  • Prostate cancer: how assessment of QoL can improve delivery of care
    Brown, M
  • Evaluation of the psychometric properties of the Functional Assessment of Cancer Therapy-Cervix questionnaire in Brazil
    Fregnani, CMS; Fregnani, JHTG; Latorre, MRDO; Almeida, AM
  • Validation of the Portuguese version of Functional Assessment of Cancer Therapy-Fatigue (FACT-F) in Brazilian cancer patients
    Ishikawa, NM; Thuler, LC; Giglio, AG; Baldotto, CS; de Andrade, CJ; Derchain, SF
  • The Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales in men with prostate cancer: reliability and validity of the Korean Version
    Hong, JH; Jeon, SS; Lee, HM; Choi, Y; Kim, S; Choi, HY
  • Psychometric properties of Functional Assessment of Cancer Therapy-Prostate (FACT-P) in Chinese patients with prostate cancer
    Wong, CKH; Choi, EPH; Tsu, JHL
  • The Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales in men with prostate cancer: reliability and validity of the Korean Version
    JH Hong, SS Jeon, HM Lee, Y Choi, S Kim, HY Choi
  • Psychometric properties of Functional Assessment of Cancer Therapy-Prostate (FACT-P) in Chinese patients with prostate cancer
    CKH Wong, EPH Choi, JHL Tsu